Gastrointestinal Stromal Tumors Progression During Adjuvant Therapy

After radical surgical resection of primary GIST, pathology evaluates the risk of postoperative recurrence according to the corresponding criteria based on the size, mitotic count, site of the primary tumor, and presence of preoperative or intraoperative rupture. The international and domestic consensus guidelines suggest that patients with primary GIST with intermediate or high risk of recurrence should receive imatinib adjuvant therapy for 1 or 3 years, respectively. The probability of tumor recurrence and metastasis during adjuvant therapy is believed to be as low as 10%. Therefore, recurrence during the adjuvant treatment period requires further research.